



Press release

SHL Telemedicine receives CFDA - Chinese FDA approval for the smartheart™

Tel Aviv/Zurich, 13 May 2014 - SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, announced that it has received the China Food and Drug Administration ("CFDA") approval for the marketing of the smartheart™ in China. The smartheart™ has already received marketing approvals in Europe, the US and Japan.

Erez Alroy, Co-CEO of SHL, commented: "With the China Food and Drug Administration ("CFDA") approval we continue broadening our international footprint. This strengthens our position as a leading provider of telehealth services and offers a large market opportunity. We will continue to invest in our international expansion, leveraging the smartheart™ platform."

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information please visit our web site at www.shl-telemedicine.com.

Contacts:

Erez Alroy
Co-CEO
P: +972 3 5612212,
ereza@shl-telemedicine.com

Martin Meier-Pfister
IRF Communications
P: +41 43 244 81 40
shl@irfcom.ch

Garth Russell / Josh Dver
KCSA Strategic Communications
P: 212-896-1250 / 212-896-1239
grussell@kcsa.com/
jdver@kcsa.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.